Diagnosis and Management of Chronic Daily Headache

Ivan Garza, M.D.,¹ and Todd J. Schwedt, M.D.²

ABSTRACT

Chronic daily headache (CDH) is a descriptive term that encompasses multiple headache diagnoses and affects ~4% of the general adult population. Chronic daily headache results in significant pain and suffering with substantial impact on quality of life, and enormous economic costs to society. Although most patients with primary CDH suffer from chronic migraine or chronic tension-type headache, other primary and secondary headache disorders can also manifest as a CDH syndrome. For CDH management to succeed, secondary headaches need to be ruled out with proper investigations when judged necessary. If the diagnosis of primary CDH is established, diagnosis of the specific CDH subtype is imperative to institute appropriate treatment. The diagnosis and management of distinct CDH entities, chronic migraine, chronic tension-type headache, new daily persistent headache, and hemicrania continua, are the primary forms of CDH and the emphasis of this review. Although, strictly speaking, medication overuse headache is a secondary form of CDH, it is also highlighted in this review given its frequent association with primary CDH.

KEYWORDS: Chronic, daily, headache, migraine, hemicrania

Chronic daily headache (CDH) is a descriptive term that encompasses several different headache diagnoses. Chronic daily headache affects 4% of the adult population in the United States and around the world.¹⁻³ The vast majority of CDH patients suffer from either chronic migraine or chronic tension-type headache. Chronic daily headache results in significant pain and suffering, reduction in quality of life, and enormous economic costs to society.⁴⁻⁵

Scher has summarized the evidence from population-based studies related to risk factors influencing the incidence, prevalence, and prognosis of CDH.⁶ Major life changes (residence change, marital status, etc.) have been associated with the onset of CDH.⁷ Nonmodifiable factors that increase the risk for CDH include female sex, low socioeconomic status, unmarried, history of head or neck trauma, and the presence of comorbid pain disorders. Modifiable risk factors for CDH include obesity, snoring and other sleep disorders, high caffeine intake, smoking, and overuse of abortive headache medications.⁸⁻⁹

Similar to all headache types, it is essential to exclude a secondary headache as the cause of CDH. Depending upon the clinical history and examination findings, further diagnostic testing may or may not be necessary. Although a complete list of causes for secondary CDH would be exhaustive, Table 1 summarizes common considerations.

If secondary headaches are ruled out, the clinician must determine the type of primary CDH the patient

¹Department of Neurology, Mayo Clinic, Rochester, Minnesota; ²Washington University Headache Center, Washington University School of Medicine, St. Louis, Missouri.

Address for correspondence and reprint requests: Ivan Garza, M.D., Assistant Professor, Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905 (e-mail: garza.ivan@mayo.edu).

has. Chronic migraine, chronic tension-type headache, new daily persistent headache, hemiconnia continua, and medication overuse headache are discussed in this review. Although medication overuse headache is a second CDH, it is included here because of the important contribution to primary CDH.

CHRONIC MIGRAINE
Chronic migraine, which affects ~2% of the world population, places a substantial burden on individuals and societies. Chronic migraine results in poorer quality of life and causes significant disability. The World Health Organization considers chronic migraine to cause disability on par with the disability secondary to quadriplegia, dementia, and active psychosis. Direct and indirect costs from migraine are estimated at more than $20 billion annually in the United States, much of which is due to chronic migraine. The average annual cost per person with chronic migraine is more than four times that associated with episodic migraine ($7750 versus $1757). Progression from episodic migraine (<15 headache days/month) to chronic migraine is referred to as “transformed migraine.” In population studies, 3% of those with infrequent episodic headaches transform to CDH each year; 6% transform to frequent episodic headaches. In clinic-based studies, 14% of those with episodic migraine transform to chronic migraine each year. Modifiable and nonmodifiable risk factors for this transformation have been described.

A detailed discussion of migraine pathophysiology is discussed in the article by Dr. Cutrer in this issue. Interictal (between migraine) and longitudinal studies of chronic migraine will hopefully lead to an improved understanding of the pathophysiology and effects of transformation from episodic migraine to chronic migraine. Elevated concentrations of vasoactive neuropeptides in the cerebrospinal fluid of chronic migraine patients suggest persistent activation of the trigemino-vascular system. Neurogenic inflammation may lead to central sensitization, a process implicated in the chronification of migraine. Functional and structural brain changes have been identified in migraine and are positively associated with increasing headache frequency and duration. Chronic migraine sufferers have increased iron deposition in the periaqueductal gray, putamen, globus pallidus, and red nucleus. They have reductions in gray and white matter density and volume in multiple regions of the brain. Chronic migraine sufferers have inferior executive function and abnormal visual motion perception even when headache free.

Diagnosis
Chronic migraine patients tend to have mild to moderate headaches associated with mild migraineous features (e.g., photophobia, phonophobia) with superimposed more-severe headaches associated with more prominent migraine features (“full-blown” migraines). In some patients, environmental hypersensitivities persist even during headache-free periods. This may include mild photophobia, phonophobia, motion-sensitivity, and cutaneous hypersensitivity/allodynia. Patients with chronic migraine have an increased frequency of comorbid psychiatric disorders, sleep disorders, fatigue, other pain, and gastrointestinal complaints. Recognition and treatment of these comorbidities can result in improved health, greater quality of life, and may potentially result in higher migraine treatment success rates. The following are the recently revised diagnostic criteria for chronic migraine:

1. Headache (tension-type and/or migraine) on ≥15 days per month for at least 3 months
2. Occurring in a patient who has had at least five attacks fulfilling criteria for migraine without aura
3. On ≥8 days per month for at least 3 months, headache has fulfilled criteria for pain and associated symptoms of migraine without aura (Criteria a and b below) or was treated and relieved by triptan(s) or ergot before the expected development of symptoms listed in Criteria a and b.
   a. Has at least two of the following:
      i. Unilateral location
      ii. Pulsating quality
      iii. Moderate or severe pain intensity
      iv. Aggravation by or causing avoidance of routine physical activity
   b. Has at least one of the following:
      i. Nausea and/or vomiting
      ii. Photophobia and phonophobia
4. No medication overuse and not attributed to another causative disorder

Table 1 Secondary Chronic Daily Headache

<table>
<thead>
<tr>
<th>Medication-overuse headache</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerebrovascular disease (cerebral venous sinus thrombosis, arteriovenous malformations, giant cell arteritis, subdural hematoma, etc.)</td>
</tr>
<tr>
<td>Altered CSF dynamics (spontaneous CSF leak, idiopathic intracranial hypertension, secondary intracranial hypertension)</td>
</tr>
<tr>
<td>Intracranial space-occupying lesions (neoplasms, others)</td>
</tr>
<tr>
<td>Posttraumatic</td>
</tr>
<tr>
<td>Infection (intra- or extracranial, sinusitis)</td>
</tr>
<tr>
<td>Musculoskeletal (cervical spine disorders, temporomandibular joint disorders)</td>
</tr>
<tr>
<td>Others</td>
</tr>
</tbody>
</table>

CSF, Cerebrospinal fluid.
Treatment
The treatment of chronic migraine focuses on prophylactic therapies, which may include avoidance of migraine triggers, pharmacotherapy, physical therapy, biobehavioral therapy, and others. Simultaneous use of these different therapeutic modalities may be needed. Identification and treatment of comorbid disorders is also required for true treatment success. Acute headache medication use needs to be limited to avoid medication overuse headache. Although complete headache eradication is not a realistic expectation, significant reductions in headache frequency and/or severity are the goal of prophylactic therapy.

PHARMACOLOGIC PROPHYLAXIS
Prophylactic medications used to treat episodic migraine are also used for the prevention of chronic migraine. Thus, first-line prophylactic medications are from the following classes: antidepressants, antiepileptics, and antihypertensives. The prophylactic medications that have been specifically studied in clinical trials of patients with chronic migraine are illustrated in Table 2. Once an effective prophylactic medication is found, it is typically continued for 3 to 6 months prior to attempting discontinuation. An effective prophylactic medication is one that decreases headache frequency by at least 50%.

**Topiramate** Two randomized, double-blind, placebo-controlled studies are available.

The larger of the two studies randomized 153 subjects to topiramate 100 mg daily and an equal number to placebo. Those in the topiramate group experienced a reduction of 6.4 ± 5.8 headache days per month from a baseline of 17.1 ± 5.4 days, as compared with a reduction of 4.7 ± 6.1 days from a baseline of 17.0 ± 5.0 days in the placebo group (p = 0.10). In the smaller of the two studies, 32 subjects were randomized to topiramate 100 mg daily and 27 were randomized to placebo. Among all subjects, topiramate significantly reduced the mean number of monthly migraine days during the third month of therapy as compared with placebo (p = 0.02).

**Gabapentin** Gabapentin has been studied as a prophylactic medication for chronic daily headache in a multicenter randomized placebo-controlled crossover study of 133 subjects (~85% with migraine). Gabapentin 2400 mg per day was associated with a greater percentage of headache-free days (mean 26.6% vs. 17.5%, p < 0.001) and reductions in headache duration, severity, and analgesic use.

**Tizanidine** Tizanidine has been studied as an adjunctive prophylactic for chronic daily headache in a multicenter, randomized, blinded, placebo-controlled study.

One hundred thirty-six subjects (~3/4 with chronic migraine) were randomized to placebo or to tizanidine titrating up from 2 mg each night to the maximum tolerated dose, or 24 mg divided among three daily doses. The median tizanidine dosage was 20 mg per day. Subjects in the tizanidine group had significant reductions in headache index as compared with the placebo group.

**Fluoxetine** Sixty-four subjects with chronic migraine were randomized in a 16-week double-blind trial of fluoxetine. Subjects were treated with 20 mg daily and then increased to 40 mg daily if needed and as tolerated. Fluoxetine-treated subjects had significant improvements as compared with the placebo group in overall headache status, mood, and headache frequency.

**Amitriptyline** Thirty-nine transformed migraine subjects participated in a prospective double-blind study of amitriptyline versus amitriptyline plus fluoxetine. Although there were not significant differences in outcomes between the two treatment groups, subjects treated with amitriptyline (8–40 mg/day) and those treated with amitriptyline plus fluoxetine (8–20 mg/day) both had reductions in headache frequency and intensity.

**Levetiracetam** An open-label study of 36 transformed migraine subjects, with or without medication overuse, investigated the effect of levetiracetam. At 3 months,

<table>
<thead>
<tr>
<th>Drug</th>
<th>Initial Dose (mg)</th>
<th>Typical Total Daily Dose (mg)</th>
<th>Common Side Effects</th>
<th>Serious Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Topiramate</td>
<td>25</td>
<td>100–200</td>
<td>Paresthesias, fatigue, weight loss</td>
<td>Acute angle closure glaucoma, metabolic acidosis, hyperthermia</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>300</td>
<td>900–2400</td>
<td>Dizziness, somnolence, fatigue, edema</td>
<td></td>
</tr>
<tr>
<td>Tizanidine</td>
<td>2</td>
<td>6–24</td>
<td>Somnolence, dry mouth, asthenia</td>
<td>Hepatitis</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>10–20</td>
<td>10–80</td>
<td>Insomnia, asthenia, tremor</td>
<td>Prolonged QT interval</td>
</tr>
<tr>
<td>Amitriptyline</td>
<td>10–25</td>
<td>50–150</td>
<td>Sedation, weight gain, constipation</td>
<td>Cardiac dyrrhythmias</td>
</tr>
<tr>
<td>Levetiracetam</td>
<td>250</td>
<td>750–2000</td>
<td>Somnolence, asthenia</td>
<td></td>
</tr>
<tr>
<td>Divalproex sodium</td>
<td>250–500</td>
<td>500–1500</td>
<td>Weight gain, tremor, nausea, alopecia</td>
<td>Pancreatitis, liver failure, thrombocytopenia</td>
</tr>
<tr>
<td>Memantine</td>
<td>5</td>
<td>5–20</td>
<td>Dizziness</td>
<td></td>
</tr>
</tbody>
</table>
ache clinic-based samples, respectively. Predictors of from 56 to 70% in population-based and specialty headache episodic migraine. Reversion rates at one year range Patients with chronic migraine may revert back to from chronic migraine. A controlled study of 30 patients with intractable transformed migraine. In an open-label study of 30 patients with intractable transformed migraine, patients were maintained on dosages between 1000 to 2500 mg. A 50% or greater reduction in headache index was found in 67% of the subjects, headache-free days per month increased from 5.5 to 17.7, and days with significant disability declined from 22 per month to 8.5 per month. The second study was a chart review of 138 chronic daily headache patients (49 with transformed migraine) being treated with divalproex sodium monotherapy. In the migraine patients, the mean decrease in migraine frequency was 65.2%.

Botulinum Toxin Although botulinum toxin type A appears to benefit a subset of patients with chronic migraine, no consistent or strong evidence is available yet to permit drawing conclusions on its efficacy in CDH (mainly transformed migraine). Further study results are required and pending.

Memantine Memantine was recently reported to induce remission of chronic migraine. An open-label study further suggests this drug may play a role in chronic migraine management. Double-blind studies are required to establish memantine’s role in chronic migraine treatment.

NONPHARMACOLOGIC THERAPY Biofeedback, relaxation therapy, cognitive–behavioral therapy, and physical therapy may be useful as adjunctive treatments for chronic migraine. A controlled study of biofeedback showed associated decreases in oxidative stress and disability from migraine. Cognitive–behavioral therapy may provide short-term and long-term reductions in headache burden. Physical therapy is associated with significant reductions in migraine burden in some studies. Furthermore, a combination of physical therapy and biofeedback has been shown to provide greater relief than physical therapy alone.

Outcome Patients with chronic migraine may revert back to episodic migraine. Reversion rates at one year range from 56 to 70% in population-based and specialty headache clinic-based samples, respectively. Predictors of reversion include withdrawal of overused medications, compliance with prophylactic medications, and regular physical exercise.

CHRONIC TENSION-TYPE HEADACHE Chronic tension-type headache is considerably less prevalent than episodic tension-type headache. A telephone survey obtained from 1993 to 1994 in Baltimore, Maryland, found an overall prevalence of 38.3% for episodic tension-type headache and a 1-year period prevalence of chronic tension-type headache of 2.2%. Chronic tension-type headache increases in prevalence until the fourth decade of life and then decreases. Chronic tension-type headache is more prevalent in women compared with men and psychiatric disorders may be risk factors for its development.

Although peripheral mechanisms apparently play a role in episodic tension-type headache pathophysiology, central mechanisms may play a larger role in chronic tension-type headache. Chronic tension-type headache sufferers had a general hypersensitivity to pain stimuli not seen in controls in a study of nociceptive processing. Central pain inhibition may be dysfunctional in chronic tension-type headache. Research using high-density electroencephalogram (EEG) brain mapping has found the supraspinal response to muscular pain to be abnormal in chronic tension-type headache sufferers. The reduced magnitude during and after induced tonic muscle pain in controls, but not in chronic tension-type headache patients, might be a consequence of impaired inhibition of the nociceptive input in chronic tension-type headache. Deficient diffuse noxious inhibitory control-like mechanisms, such as seen in generalized chronic pain like fibromyalgia, have been found in chronic tension-type headache. Voxel-based morphometry and magnetic resonance imaging (MRI) have identified a significant gray matter decrease in regions involved in pain processing in chronic tension-type headache patients.

Diagnosis Because it largely consists of head pain alone, tension-type headache is frequently called “the featureless headache.” Chronic tension-type headache typically evolves from episodic tension-type headache and is usually bilateral, pressure-like in quality, and mildly to moderately intense. “Wearing a tight hat, wearing a tight band around the head, or wearing a heavy burden on the head” are frequent descriptions used by patients. The following are current International Classification of Headache Disorders, 2nd edition (ICHD-2) criteria for chronic tension-type headache.

1. Headache occurring on ≥15 days per month on average for >3 months (≥180 days per year) and fulfilling criteria 2–4
2. Headache lasts hours or may be continuous
3. Headache has at least two of the following characteristics:
a. Bilateral location
b. Pressing/tightening (nonpulsating) quality
c. Mild or moderate intensity
d. Not aggravated by routine physical activity such as walking or climbing stairs

4. Both of the following:
   a. No more than one of photophobia, phonophobia, or mild nausea
   b. Neither moderate or severe nausea nor vomiting

5. Not attributed to another disorder

Of note, the presence of migraine attacks superimposed on a background daily “tension-type” headache could suggest that chronic migraine may be the right diagnosis rather than chronic tension-type headache.57

Treatment
Pharmacologic prophylaxis is the mainstay of treatment. Similar to chronic migraine, effective therapy is continued for at least 3 to 6 months prior to attempting discontinuation.58 Table 3 summarizes prophylactic medications studied specifically in chronic tension-type headache.

### PHARMACOLOGIC PROPHYLAXIS

**Amitriptyline**  
Amitriptyline is the drug of choice, typically at doses ranging from 25 mg to 100 mg per day.50 This is the only antidepressant used in chronic tension-type headache that has demonstrated statistically significant benefit in several trials.58 Amitriptyline has an estimated therapeutic gain of ~30% based on published trials.59,60

**Nortriptyline**  
Nortriptyline has a more favorable side effect profile than amitriptyline.61 In a randomized placebo-controlled trial, patients with chronic tension-type headache who did not tolerate amitriptyline were switched to nortriptyline at doses of up to 75 mg/day.62 Both antidepressants produced larger reductions in headache, analgesic medication use, and headache-related disability than placebo.62

**Protriptyline**  
Protriptyline Twenty-five adult female chronic tension-type headache sufferers were studied using protriptyline 20 mg every morning. Eighty-six percent had fewer headaches per month, and 73% had a ≥50% reduction in headache attacks per month.63 In contrast to the weight gain associated with other tricyclic antidepressants, patients lost slightly over three pounds during the study.63 No placebo group was used.

**Mirtazapine**  
Bendsten studied mirtazapine in a randomized, double-blind, placebo-controlled, crossover trial. Mirtazapine 15 to 30 mg/day or placebo was given for 8 weeks separated by a 2-week washout period.60 Mirtazapine reduced the area-under-the-headache curve by 34% more than placebo. The drug also reduced headache frequency, duration, and intensity significantly more than placebo. The efficacy of mirtazapine was similar to that of amitriptyline (a therapeutic gain of ~30%).59,60

**Topiramate**  
In an open study, topiramate (daily dose 25 to 100 mg/day) resulted in a 50% reduction in headache frequency in 73% of 46 chronic tension-type headache patients at weeks 13 to 24.64 Average headache intensity decreased from 6.13 to 2.07 on the visual analogue scale.64 Randomized controlled trials are needed to define topiramate’s role in the management of chronic tension-type headache.

**Sodium Valproate**  
Sodium valproate (500 mg twice per day) was associated with greater reductions in pain frequency than placebo in 41 chronic tension-type headache subjects in a prospective, double-blind, randomized, placebo-controlled trial.65 The Visual Analog Scale pain rating did not decrease in the active group.

**Tizanidine**  
Tizanidine (6 to 18 mg/day in divided doses) was found to be superior to placebo in a randomized, double-blind, crossover study in women with chronic tension-type headache.66 A separate randomized, double-blind, parallel-group study, however, failed to demonstrate superiority to placebo.67 To date, one

### Table 3  Prophylactic Agents Studied in Chronic Tension-type Headache

<table>
<thead>
<tr>
<th>Drug</th>
<th>Initial Dose (mg)</th>
<th>Typical Total Daily Dose (mg)</th>
<th>Common Side Effects</th>
<th>Serious Side Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amitriptyline</td>
<td>10–25</td>
<td>25–100</td>
<td>Sedation, weight gain, constipation</td>
<td>Cardiac dysrhythmias</td>
</tr>
<tr>
<td>Nortriptyline</td>
<td>10–25</td>
<td>25–100</td>
<td>Sedation, weight gain, constipation</td>
<td>Cardiac dysrhythmias</td>
</tr>
<tr>
<td>Protriptyline</td>
<td>5–10</td>
<td>10–30</td>
<td>Sedation, weight change, constipation</td>
<td>Cardiac dysrhythmias</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>15</td>
<td>15–45</td>
<td>Somnolence, dry mouth</td>
<td>Neutropenia</td>
</tr>
<tr>
<td>Topiramate</td>
<td>25</td>
<td>100–200</td>
<td>Paresthesias, fatigue, weight loss</td>
<td>Acute angle closure glaucoma, metabolic acidosis, hyperthermia</td>
</tr>
<tr>
<td>Sodium valproate</td>
<td>250–500</td>
<td>500–1000</td>
<td>Weight gain, tremor, nausea, alopecia</td>
<td>Pancreatitis, liver failure, thrombocytopenia</td>
</tr>
</tbody>
</table>
cannot draw firm conclusions for the potential role of tizanidine in chronic tension-type headache.\(^{58}\)

**Others** Citalopram and paroxetine have not proven beneficial in chronic tension-type headache prophylaxis.\(^{59,68,69}\) Further research is needed to determine the potential efficacy of venlafaxine\(^{70}\) and buspirone.\(^{71}\) There is no evidence for a beneficial effect of botulinum toxin in chronic tension-type headache.\(^{72}\)

**COMPLEMENTARY/ALTERNATIVE TREATMENT**

In chronic tension-type headache sufferers with coexistent depression, simultaneous treatment for both disorders has shown benefit.\(^{73}\) Combination treatment is superior to pharmacotherapy or behavioral therapy alone.\(^{58}\) Combination treatment with behavioral stress management was more likely to achieve clinically significant (≥50%) reductions in headache index scores (64% of participants) than antidepressant medication (38% of participants), stress management therapy (35%), or placebo (29%) in a randomized placebo-controlled trial of 203 chronic tension-type headache subjects.\(^{62}\)

The potential role of acupuncture in chronic tension-type headache is yet to be defined. In one study, relaxation training induced the best benefit compared with acupuncture and physical training.\(^{74}\) The potential role of hypnosis\(^{75}\) and structured massage\(^{76}\) remain to be determined. Other noninvasive physical treatments with some evidence in chronic tension-type headache prophylaxis include spinal manipulation, cranial electotherapy, transcutaneous electrical nerve stimulation (TENS)/electrical neurotransmitter modulation combination, and automassage/TENS/stretching combination.\(^{77}\)

**ACUTE PHARMACOLOGIC THERAPY**

Simple analgesics and nonsteroidal antiinflammatory drugs (NSAIDs) remain as the pillar of abortive treatment in tension-type headache.\(^{50}\) Acetaminophen/isonethane/ dichloralphenazone frequently helps more severe episodes not responding to NSAIDs.

**MEDICATION-OVERUSE HEADACHE**

Medication-overuse headache frequently coexists with primary CDH and can preclude effective therapy of the latter. In some cases medication overuse headache may be responsible for the development or maintenance of a CDH syndrome\(^ {78}\); in other cases, medication overuse is the result of frequent headaches. Prophylactic medications for primary CDH are more likely to provide benefit following successful medication-overuse headache management.\(^ {79}\)

The prevalence of medication-overuse headache in the general population is ~1.5%.\(^ {80}\) The female to male ratio is 3.5:1.\(^ {81}\) In tertiary headache clinics throughout America, up to 50 to 80% of patients have medication-overuse headache.\(^ {80}\) By far, migraine is the most common primary headache disorder associated with medication-overuse headache. In a meta-analysis summarizing 29 studies, 65% of 2612 patients with chronic medication overuse headache had migraine, 27% had tension-type, and 8% had mixed or other type of primary headache.\(^ {81}\)

The risk for medication overuse headache development differs with individual substances. Opioids, butalbital-containing analgesics, and aspirin/acetaminophen/caffeine combinations are high risk; triptans are moderate risk; and NSAIDs are low risk.\(^ {82}\) In a recent longitudinal population-based study, any use of barbiturates and opiates was associated with increased risk of transformed migraine.\(^ {83}\) Critical dose of opiate exposure was around 8 days per month, and the effect was more pronounced in men.\(^ {84}\) Critical dose of barbiturate exposure was around 5 days per month and the effect was more pronounced in women.\(^ {84}\) Triptans and NSAIDs induced migraine progression in those with high frequency of migraine at baseline (10–14 days per month), but not overall.\(^ {84}\)

Multiple mechanisms may be involved in the development of medication-overuse headache.\(^ {85}\) Development of medication-overuse headache appears to be restricted to those with underlying headache disorders as it does not develop de novo in those without headaches who overuse the same medications.\(^ {85,86}\) Neurophysiologic studies have shown facilitation of trigeminal and somatic nociceptive systems in medication-overuse headache, mainly mediated at a supraspinal level.\(^ {87}\) This suggests central sensitization (a process also involved in migraine pathophysiology) may also be involved in medication-overuse headache pathophysiology. Studies using 18-fluorodeoxyglucose positron emission tomography (18-FDG PET) have identified reversible metabolic changes in pain processing structures and persistent orbitofrontal hypofunction in migraine patients with coexistent medication overuse headache.\(^ {88}\) Chronic morphine exposure results in increased descending facilitation from the rostral\(^ {88}\) ventromedial medulla and increased excitatory neurotransmission at the dorsal horn.\(^ {89}\) Sometimes, substance addiction may be the base for medication overuse headache. Others appear to be treating pain and a comorbid anxiety disorder with the same medication (e.g., opiates).\(^ {90}\) Out of 895 patients with medication overuse headache studied in a prospective fashion, 68% met three of five substance-dependence criteria according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) versus 20% in those without medication-overuse headache.\(^ {91}\) Fear of headache, anticipatory anxiety, obsessive drug-taking behaviors, and psychological drug dependence may also help induce and then sustain medication-overuse headache.\(^ {90}\)
Diagnosis
As discussed earlier, medication-overuse headache patients typically have a primary headache disorder that increased in frequency and led to increased analgesic consumption and then medication-overuse headache. It is not uncommon for patients to take frequent analgesics solely to prevent a severe analgesic-withdrawal headache. Medication overuse headache varies in its characteristics (severity, location, type) and is frequently associated with nausea, asthenia, and cognitive difficulties (impaired memory, poor concentration, irritability). If a CDH sufferer is taking analgesics more than 2 to 3 days per week on average, medication-overuse headache should always be suspected. The following are current ICHD-2 diagnostic criteria for medication overuse headache. Please note that the type of medication overused is important for proper diagnosis.

1. Headache present on ≥15 days/month
2. Regular overuse for >3 months of one or more acute/symptomatic treatment drugs
   a. Ergotamine, triptans, opioids, or combination analgesic medications on ≥10 days/month on a regular basis for >3 months
   b. Simple analgesics or any combination of ergotamine, triptans, analgesic opioids on ≥15 days/month on a regular basis for >3 months without overuse of any single class alone
3. Headache has developed or markedly worsened during medication overuse

Treatment
Abrupt drug withdrawal remains the treatment of choice when dangerous physical withdrawal is not a concern. Proper management of medication-overuse headache should include the following steps:

1. Patient education
2. Withdrawal of offending medication
3. “Bridging” aimed at symptomatic relief during medication withdrawal
4. Establish new acute and preventive headache treatment regimen
5. Follow-up and headache reassessment
6. Relapse prevention

Patient Education
Patients with medication-overuse headache need to understand that as long as they are overusing analgesics, headache preventives may be less effective or not effective at all. They need to be educated on why analgesic overuse is detrimental. The majority of medication-overuse headache patients benefit from drug withdrawal. Benefit may be from the withdrawal alone or from a “reparative” change from treatment failure to favorable response to medical management.

Withdrawal of the Offending Medication
During analgesic withdrawal, headaches frequently exacerbate before starting to improve. Nausea, vomiting, restlessness, anxiety, and sleep disturbances may also occur during withdrawal. Withdrawal symptoms usually last 2 to 10 days (mean 3.5 days), but can endure for 2 to 4 weeks. Although many physicians prefer inpatient programs for withdrawal, most patients can be managed on an outpatient basis. A recent prospective, randomized trial in patients with migraine and superimposed medication-overuse headache showed that simple, strong advice was as effective as structured inpatient and outpatient detoxification programs in achieving medication withdrawal. The mean success rate of withdrawal treatment at 1 to 6 months was 72.4% in a meta-analysis.

Bridging
The goal of “bridging” is to provide symptomatic relief during acute medication withdrawal. No clear guidelines or consensus recommendations exist. Bridging recommendations are based on case series, retrospective chart reviews, prospective uncontrolled studies, and expert opinion. Some studies support the use of corticosteroids; others do not. Further randomized, placebo-controlled trials are needed to clarify the potential role of corticosteroids in medication-overuse headache management. Antiemetics are often prescribed in addition to the following published strategies.

ORAL
Naproxen 500 mg twice a day until withdrawal is complete.
Naproxen sodium 550 mg twice a day for 2 to 4 weeks.
Naproxen sodium 550 mg twice a day for 1 week, then once a day for 1 week.
Prednisone 60 mg/day, decrease by 20 mg every 2 days (total 6 days).
Prednisone 100 mg for 5 days.

INJECTED
Intravenous (IV) methylprednisolone 100 to 200 mg every 12 hours for 2 to 3 days.
IV or intramuscular (IM) dexamethasone 8 to 20 mg/day, tapering over 2 to 3 days.
IV hydrocortisone 100 mg every 6 hours for 24 hours; every 8 hours for 24 hours; then every 12 hours for 24 hours.
Repetitive IV dihydroergotamine (DHE; inpatient): IV metoclopramide 10 mg, followed by 0.5 mg IV DHE.
Doses adjusted based on headache severity and side effects.\(^{100}\)

Continuous IV DHE (inpatient): 3 mg of DHE in 1000 mL of normal saline at 42 mL/h by IV infusion pump, totaling 3 mg of DHE administered at constant rate over 24 hours.\(^{101}\)

Subcutaneous DHE (outpatient): 1 mg twice a day for 1 week followed by 0.5 mg twice a day for 1 week, or 1 mg twice a day for 1 week followed by 1 mg every day for 1 week.\(^{89}\)

IV valproate sodium: loading dose of 15 mg/kg followed by daily maintenance of 5 mg/kg every 8 hours for 12 to 48 hours.\(^{102}\)

IV prochlorperazine starting with 5 mg to 10 mg every 8 hours, with dosage adjustment according to efficacy and side effects until headache-free.\(^{99}\)

Establish Appropriate Headache Prevention
Whether pharmacologic prophylaxis should be started at the time of medication withdrawal remains an ongoing dispute.\(^{103}\) Because most patients will require long-term preventives, the authors recommend starting such treatment at the time of withdrawal. Preventives are chosen according to the type of underlying primary headache disorder.

Follow-up and Headache Reassessment
Once the overused medications have been withdrawn, patients frequently return to a pattern of intermittent headaches. These headaches need to be classified and treated accordingly.

Relapse Prevention
Most relapses occur in the first year following withdrawal.\(^{104}\) In general, avoidance of opiates and/or butalbital for the regular management of primary headache disorders is recommended. Limitations for the frequency of analgesic intake should be explained: triptan or combination analgesic use should be limited to 9 or fewer days a month on average and NSAIDs to 15 or fewer days a month to prevent medication-overuse headache relapse.\(^{105}\) The identification and management of comorbidities (anxiety, etc.) that may contribute to medication overuse headache development and preservation are of paramount importance to prevent medication overuse headache relapse.\(^{90}\)

NEW DAILY PERSISTENT HEADACHE
New daily persistent headache, one of the most treatment refractory headaches, is a headache that begins one day and typically does not remit.\(^{106}\) New daily persistent headache affects women more than men with reported ratios of 1.3:1 and 2.5:1.0 and can essentially affect all age groups.\(^{107–109}\) Peak age of onset is in the second and third decades for women and the fifth decade in men.\(^{109}\) Overall mean age of onset is 35 years of age.\(^{108}\) Although new daily persistent headache is estimated to occur infrequently in the general population, the exact frequency is unknown.\(^{108}\) In headache clinics, however, ~1 in 10 CDH patients have new daily persistent headache.\(^{110}\)

The etiology of new daily persistent headache is not well understood. Although the nature of the associations is unclear, infection, flu-like illness, surgery, and stressful life events may precede new daily persistent headache.\(^{109}\) How these may result in new daily persistent headache is unknown and in many patients, no precipitating factors exist.\(^{108}\) Possible associations between new daily persistent headache and Epstein-Barr virus (EBV), herpes simplex virus (HSV), and cytomegalovirus (CMV) have been suggested but remain unproven.\(^{109,111–114}\)

**Diagnosis**
The vast majority of patients (up to 82%) can vividly recall the exact date the headache started.\(^{109}\) In most, ~80%, the pain is continuous.\(^{108,109}\) Pain intensity tends to be moderate, although many patients experience severe pain.\(^{109}\) Clinical features vary significantly. Headaches may have primarily migraine features (photophobia, nausea, etc.) or be “featureless” and reminiscent of chronic tension-type headache.\(^{107–109}\) Secondary headache disorders, including those due to spontaneous cerebrospinal (CSF) leaks and cerebral venous sinus thrombosis, need to be ruled out.\(^{55,106}\) MRI of the brain with gadolinium and magnetic resonance venography (MRV) should be considered. Clinical judgment guides further investigations, if any. Current ICHD-2 diagnostic criteria for new daily persistent headache are as follows:\(^{55}\)

1. Headache for >3 months fulfilling Criteria 2 through 4
2. Headache is daily and unremitting from onset or from <3 days from onset
3. At least two of the following pain characteristics:
   a. Bilateral location
   b. Pressing/tightening (nonpulsating) quality
   c. Mild or moderate intensity
4. Not aggravated by routine physical activity, such as walking or climbing stairs
5. Both of the following:
   a. No more than one of photophobia, phonophobia, or mild nausea
   b. Neither moderate or severe nausea nor vomiting
6. Not attributed to another disorder
Of note, although the above criteria reflect essentially a chronic tension-type headache phenotype, migraineous features are frequently reported. Diagnostic criteria will likely be modified as knowledge about this disorder expands.

**Treatment**

New daily persistent headache can endure for many years (even decades) and can be disabling. Despite proper treatment, the headache frequently does not abate. Takase found treatment to be very effective in 27%, moderately effective in 3%, mildly effective in 20%, and not effective in 50% of 30 new daily persistent headache sufferers. In agreement with other headache specialists, we recommend classifying the dominant headache phenotype, whether it is migraine or tension-type, and treat with preventives accordingly.

New daily persistent headache has been reported to take one of the following courses: a self-limited one typically resolving without treatment within several months, or a refractory course resistant to aggressive treatment. Although most patients are headache free at 2 years in some series, in others (and in practice) new daily persistent headache may be refractory to treatment for many years.

**Hemicrania Continua**

Hemicrania continua is a one-sided continuous headache of moderate severity with superimposed severe exacerbations of pain often associated with ipsilateral autonomic symptoms. The frequency of hemicrania continua in the general population is unknown. Hemicrania continua may begin at any age, but peaks in the third decade of life. It is twice as common in women than men.

The pathophysiology of hemicrania continua is incompletely understood. However, a PET study of seven patients with hemicrania continua showed significant activation of the contralateral posterior hypothalamus and ipsilateral rostral pons during baseline pain that were blocked by administration of indomethacin. PET in one patient with hemicrania continua without autonomic features, who had dorsal pontine activation but no hypothalamic activation, suggests that the hypothalamus may play a role in autonomic activation, perhaps via disinhibition of the trigeminal-autonomic reflex.

**Diagnosis**

Hemicrania continua is a unilateral headache that is continuous in nature. Continuous pain is generally moderate in intensity. There are superimposed severe attacks of pain that last minutes to several days classically associated with autonomic features (lacrimation, miosis, etc.). Although not fulfilling the diagnostic criteria, a subgroup of patients with continuous one-sided headaches completely responsive to indomethacin do not have autonomic symptoms. Mild migraineous features may be present, and some patients develop superimposed headaches consistent with migraine headaches. Ipsilateral ocular discomfort or an ocular foreign body sensation and a superimposed stabbing headache (“jabs and jolts”) are often reported. ICHD-2 diagnostic criteria are as follows:

1. Headache for >3 months fulfilling Criteria 2 through 4
2. All of the following characteristics:
   a. Unilateral pain without side-shift
   b. Daily and continuous, without pain-free periods
   c. Moderate intensity, but with exacerbations of severe pain
3. At least one of the following autonomic features occurs during exacerbations and ipsilateral to the side of pain:
   a. Conjunctival injection and/or lacrimation
   b. Nasal congestion and/or rhinorrhea
   c. Ptosis and/or miosis
4. Complete response to therapeutic doses of indomethacin
5. Not attributed to another disorder

Secondary headaches mimicking primary hemicrania continua (including response to indomethacin) have been reported, including internal carotid artery dissection, unruptured aneurysm, pineal cyst, pituitary tumor, ipsilateral mesenchymal tumor of the sphenoidal bone involving the clinoid process at the base of the skull, lung adenocarcinoma, and pontine stroke. Diagnostic studies must therefore be ordered as necessary.

If hemicrania continua is suspected, an oral indomethacin test can be used for the diagnosis of hemicrania continua. One of several methods is as follows: 50 mg twice per day for 3 days, 50 mg three times per day for 3 days, 50 mg four times per day for 3 days. Indomethacin response is typically fast. In a prospective study of 12 hemicrania continua patients, complete pain relief was obtained within 48 hours in all cases, within 24 hours in 10 of the patients, and within 8 hours in nine. Completion of the test without headache resolution is considered a failed trial.

**Treatment**

Due to absolute response to indomethacin, it is the treatment of choice for hemicrania continua. The appropriate dose will vary among patients. The initial dose is that dose which results in resolution of headache, determined during the diagnostic indomethacin trial. Oral doses ranging from 25 mg to 300 mg per day
have been reported effective. However, given adverse side effects of indomethacin, the lowest effective dose is the desired dose. Periodic attempts to decrease the dose should be made. Potential side effects from indomethacin are numerous. Administration of indomethacin with food can reduce gastrointestinal side effects. Treatment with gastric mucosal protectants, such as proton-pump inhibitors, may also decrease this risk and is common practice. Many of these potential side effects are dose-related. Approximately one of three patients report side effects attributable to indomethacin therapy. Contraindications to treatment with indomethacin and/or discontinuation due to intolerance have led to the search for alternative therapies. There have been case reports of efficacy with melatonin, topiramate, verapamil, cox-2 inhibitors, gabapentin, botulinum toxin type A, and occipital nerve stimulation.

REFERENCES

164 SEMINARS IN NEUROLOGY/VOLUME 30, NUMBER 2 2010

a double-blind, placebo-controlled, multicenter outcome study. Headache 2002;42(6):470–482


47. Bendtsen L, Jensen R. Tension-type headache: the most common, but also the most neglected, headache disorder. Curr Opin Neurol 2006;19(3):305–309


82. Smith TR, Stoneman J. Medication overuse headache from antimigraine therapy: clinical features, pathogenesis and management. Drugs 2004;64(22):2503–2514


96. Diener HC. How to treat medication-overuse headache: prednisolone or no prednisolone? Neurology 2007;69(1):14–15


133. Rozen TD. Melatonin responsive hemicrania continua. Headache 2006;46(7):1203–1204
138. Garza I, Cutter F. Pain relief and persistence of dysautonomic features in a patient with hemicrania continua responsive to botulinum toxin type A. Cephalalgia 2009; June 10 (Epub ahead of print)